Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
Basic Trial Information
|Phase II||Treatment||Active||18 and over||BRE12-158|
This study will test the theory that therapy designed for each individual's tumor will
improve outcomes over standard of care in a population that needs a better standard.
Further Study Information
OUTLINE: This is a multi-center trial.
DNA from archived tumor samples collected at the time of surgery (residual disease post
neoadjuvant chemotherapy) will be extracted and sequenced. The resulting sequencing data
will be interrogated for known genomic drivers of sensitivity or resistance to existing FDA
CANCER GENOMICS TUMOR BOARD (CGTB):
Realizing that optimal treatment recommendations cannot be made based on sequencing data
alone, the CGTB will be responsible for the final treatment recommendation. The CGTB will
consider the genomic data along with the patient's prior treatment history, ongoing
toxicities, and comorbidities. Preference will be given to the treatment identified by the
sequencing data unless a significant clinical or safety contraindication exists for that
therapy. All participants and investigators will be blinded to sequencing results and CGTB
deliberations until the time of relapse.
PARTICIPANTS WITH A CGTB TREATMENT RECOMMENDATION:
Participants with a CGTB recommendation will be randomized to Experimental Arm A
(genomically directed monotherapy) or Control Arm B (standard therapy).
EXPERIMENTAL ARM A (GENOMICALLY DIRECTED MONOTHERAPY):
Participants randomized to Experimental Arm A will receive an FDA approved drug at standard
dose for four cycles (12-16 weeks total duration, depending on cycle length). Clinical and
laboratory monitoring and dose-reductions will follow the FDA package insert guidelines.
TOP GENOMIC ACTIONABLE BIOMARKERS/PATHWAYS AND DRUG RECOMMENDATIONS:
1. PIK3CA, PTEN: Everolimus
2. TOP2A: Doxorubicin
3. PARP1, BRCA1: Cisplatin and Olaparib
4. VEGFA: Bevacizumab
5. TYMP: Capecitabine
6. SSTR2: Octreotide
7. MGMT: Temozolomide
8. MYC: Paclitaxel
9. EGFR: Cetuximab
10. COX2: Celecoxib
11. hENT: Gemcitabine
12. MET: Crizotinib
CONTROL ARM B (STANDARD THERAPY); Recently, a randomized phase III trial of over 900
HER2-negative patients demonstrated an improvement in disease-free survival (DFS) and
overall survival (OS) for the addition of 8 cycles of capecitabine in the post-neoadjuvant
setting. The hazard ratios were also significant in the triple negative subgroup. Thus,
capecitabine can be considered a standard option in this setting. As this represents only a
single trial (with prior data not demonstrating benefit for the addition of capecitabine in
the neoadjuvant nor adjuvant settings in unselected patients), observation can be considered
an option as directed by the treating physician. While not recommended, other therapies can
be used as deemed appropriate by the treating physician.
In the event of disease progression on the control arm, patient sequencing results will be
forwarded to the treating physician.
PARTICIPANTS WITH NO CGTB RECOMMENDATION:
Participants may have no CGTB recommendation either because 1) sequencing did not identify a
matched drug or 2) the matched drug was contraindicated. These participants will be assigned
to Control Arm B and treated as described above for Control Arm B. As the outcome of
participants without an 'actionable' genomically directed therapy may differ, the primary
analysis will include only participants randomized to Control Arm B.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 14 days prior
to study registration
Life Expectancy: Not Specified
Adequate laboratory values must be obtained within 14 days prior to study registration:
Hemoglobin (Hgb) ≥ 9.0 g/dL
Platelets ≥ 100 K/mm3
Absolute neutrophil count (ANC) ≥ 1.5 K/mm3
Bilirubin ≤ 1.5 x ULN (except in participants with documented Gilbert's disease, who
must have a total bilirubin ≤ 3.0 mg/dL)
Aspartate aminotransferase (AST, SGOT) ≤ 2.5 x ULN
Alanine aminotransferase (ALT, SGPT) ≤ 2.5 x ULN
Calculated creatinine clearance of ≥ 50 cc/min using the Cockcroft-Gault formula
Left ventricular ejection fraction within normal limits obtained within 30 days prior
to study registration. NOTE: Participants with an unstable angina or myocardial
infarction within 12 months of study registration are excluded.
No clinically significant arrhythmia or baseline ECG abnormalities in the opinion of
the treating physician
Must have histologically or cytologically confirmed triple negative (ER-/PR-/HER2-)
invasive breast cancer, clinical stage I-III at diagnosis (AJCC 6th edition) based on
initial evaluation by physical examination and/or breast imaging prior to study
registration. NOTE: ER, PR and HER2 status will be confirmed by central pathology
review prior to randomization. ER and PR will be considered negative if ≤ 1% of cells
stain weakly positive. HER2 will be considered negative if scored 0 or 1+ by
immunohistochemistry (IHC) or 2+ by IHC associated with a fluorescence in situ
hybridization (FISH) ratio of < 2.0 or < 6 copies per cell.
Must have completed preoperative (neoadjuvant) chemotherapy. NOTE: Acceptable
preoperative regimens include an anthracycline or a taxane, or both. Participants who
received preoperative therapy as part of a clinical trial may enroll. Participants
may not have received adjuvant chemotherapy after surgery prior to randomization.
Bisphosphonate use is allowed.
Must have completed definitive resection of primary tumor. The most recent surgery
for breast cancer must have been completed at least 14 days prior (but no more than
84 days prior) to study registration. NOTE: Negative margins for both invasive and
ductal carcinoma in situ (DCIS) are desirable, however participants with positive
margins may enroll if the treatment team believes no further surgery is possible and
patient has received radiotherapy. Participants with margins positive for lobular
carcinoma in situ (LCIS) are eligible. Either mastectomy or breast conserving surgery
(including lumpectomy or partial mastectomy) is acceptable.
Must have significant residual invasive disease at the time of definitive surgery
following preoperative chemotherapy. Significant residual disease is defined as at
least one of the following:
Residual Cancer Burden (RBC) classification II or III6
Residual invasive disease in the breast measuring at least 2 cm. The presence of
DCIS without invasion does not qualify as residual disease in the breast.
Residual invasive disease in the breast measuring at least 1cm with any lymph
node involvement (does not include metastases in lymph node which are only
detected by immunohistochemistry).
Any lymph node involvement that results in 20% cellularity or greater regardless
of primary tumor site involvement (includes no residual disease in the breast).
Must have an FFPE tumor block with tumor cellularity of 20% or greater. NOTE: Prior
to randomization, the tumor cellularity will be confirmed by central pathology review
and percent values will be double checked at Paradigm (a Next Generation Sequencing
Whole breast radiotherapy is required for participants who underwent
breast-conserving therapy, including lumpectomy or partial mastectomy.
Participants must have completed radiotherapy at least 14 days prior (but no
more than 84 days prior) to study registration.
Post-mastectomy radiotherapy is required for all participants with a primary
tumor ≥ 5 cm or involvement of ≥ 4 lymph nodes. For participants with primary
tumors < 5 cm or with < 4 involved lymph nodes, provision of post-mastectomy
radiotherapy is at the discretion of the treating physician. Study registration
must occur within 84 days of completion of radiation.
For radiation required prior to surgery, the participant must register within 84
days of surgery. Also, participants in this situation would not be required to
have additional post-mastectomy radiation therapy.
For those participants who do not require radiation, registration must be within
84 days of surgery.
Age ≥ 18 years at the time of consent.
Written informed consent and HIPAA authorization for release of personal health
information. HIPAA authorization may be included in the informed consent or may be
obtained separately. NOTE: Central pathology review may be conducted any time after
definitive surgery. Consenting participants may be pre-registered to the study and
proceed with central pathology review before full eligibility has been confirmed.
However ALL of the eligibility criteria must be met and formal study registration
completed prior to submission of the sample for sequencing.
Must consent to allow submission of adequate archived tumor tissue sample from
definitive surgery for genomic assessment of tumor.
Must consent to collection of whole blood samples for genomic analysis
Women and men of childbearing potential must be willing to use an effective method of
contraception (e.g. hormonal or barrier method of birth control; abstinence) from the
time consent is signed until 4 weeks after protocol therapy discontinuation.
Women of childbearing potential must have a negative pregnancy test within 30 days
prior to study registration. Women should be counseled regarding acceptable birth
control methods to utilize from the time of screening to start of treatment. If prior
to treatment after discussion with the subject it is felt by the treating physician
there is a possibility the subject is pregnant a pregnancy test should be repeated.
Women of childbearing potential must have a negative pregnancy test within 30 days prior
to study registration.
Women must not be breastfeeding.
No stage IV (metastatic) disease, however no specific staging studies are required in
the absence of symptoms or physical exam findings that would suggest distant disease.
No treatment with any investigational agent within 30 days prior to study
No history of chronic hepatitis B or or untreated hepatitis C.
No clinically significant infections as judged by the treating physician.
No active second malignancy (except non-melanomatous skin cancer or incidental
prostate cancer found on cystectomy): Active second malignancy is defined as a
current need for cancer therapy or a high possibility (> 30%) of recurrence during
the study. Previous contralateral breast cancer is allowable unless it meets "active"
criteria as stated above.
Trial Contact Information
Trial Lead Organizations / Sponsors / Collaborators
Bryan Schneider, MD
- Hoosier Cancer Research Network
- Vera Bradley Foundation for Breast Cancer
- Walther Cancer Institute
- Strategic Research Initiative Grant through IUSCC
University of Alabama at Birmingham Cancer Center
Carla Isadora Falkson
Carla Isadora Falkson
Emory University/Winship Cancer Institute
University of Chicago Comprehensive Cancer Center
Indiana University/Melvin and Bren Simon Cancer Center
Bryan Paul Schneider
Bryan Paul Schneider
Link to the current ClinicalTrials.gov record.
NLM Identifier NCT02101385
Note: Information about participating sites on pharmaceutical industry trials may be incomplete. Please visit the ClinicalTrials.gov record via the link above for more information about participating sites.